



Best Expertise vs Conflicts of Interest: Striking the Right Balance

Nikos Dedes, Chair, Positive Voice
London, 6 September 2013

General Remarks

- EMA's speed of response (exceptional)
- Taxonomy
 - Decision Making Bodies vs Advisory Groups (should be further developed)
 - Direct vs Indirect (greatest is not the obvious)
 - Risk Level (defensive attitude)
- Scarcity of Patient Experts
- Integrity, Impartiality & Reputation

EMA's Speed



Various Thoughts

- EMA's speed of response (exceptional)
- Taxonomy
 - Decision Making Bodies vs Advisory (should be further developed)
 - Direct vs Indirect (greatest is not the obvious)
 - Risk Level (defensive attitude)
- Scarcity of Patient Experts
- Integrity, Impartiality & Reputation

Risk Level 1



Various Thoughts

- EMA's speed of response (exceptional)
- Taxonomy
 - Decision Making Bodies vs Advisory (should be further developed)
 - Direct vs Indirect (greatest is not the obvious)
 - Risk Level (defensive attitude)
- Scarcity of Patient Experts
- Integrity, Impartiality & Reputation

Patient Experts

- Provide understandable information to patients
- Engage in, influence, expedite drug Research & Development and Phase IV trial (public or industry)
- Review Clinical trial protocols and informed consent
- Participate in Clinical Guidelines, HTA, Pricing, Health Policy, Media
- Contribute in Benefit/Risk assessment (authorisation & Pharmacovigilance)
- Strive for optimal balance between: Equitable Access – Health Systems Sustainability – Innovation

Thank You